Repare shareholders approve acquisition by XenoTherapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.
January 16, 2026 4:58 PM ESTCAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)-- Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of all of the issued and outstanding common shares of the Company (the Common Shares and the holders of the Common Shares, the Shareholders) by XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly Xeno) a non-profit biotechnology company, by way of a statutory plan of arrangement (the Transaction or the Arrangement) at the special meeting of Shareholders held today (the Meeting).
The special resolution approving the Arrangement was approved... More
